Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Accumulated Expenses data on file, last reported at $25.5 million in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $25.5 million, down 14.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $25.5 million (down 14.59% YoY), and the FY2025 annual result was $25.5 million, down 14.59% from the prior year.
• Accumulated Expenses slipped to $25.5 million in Q4 2025 per INBX's latest filing, from $27.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $43.3 million in Q4 2023 and troughed at $23.9 million in Q2 2024.
• A 3-year average of $30.1 million and a median of $29.2 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses tumbled 30.96% in 2024, then increased 19.35% in 2025.
• A 3-year view of Accumulated Expenses shows it stood at $43.3 million in 2023, then plunged by 30.96% to $29.9 million in 2024, then retreated by 14.59% to $25.5 million in 2025.
• Business Quant data shows INBX's Accumulated Expenses at $25.5 million in Q4 2025, $27.0 million in Q3 2025, and $28.5 million in Q2 2025.